On Labor Day Consider the...Mesothelioma is one of many cancers that is still considered to be incurable, and the tragedy is that mesothelioma is an entirely preventable disease….
Posted on Monday, Feb 1, 2016
Featured Story
Olive Leaf Compound May Halt Mesothelioma Growth
Americans have long envied the longevity of Europeans along the Mediterranean Sea. Their good health has been attributed to their healthy lifestyle and their diet, known as the Mediterranean diet, of fresh fruits and vegetables, olive oil, nuts and an occasional indulgence in a glass of red wine. Now, new research suggests that one aspect …
For Your Family
Recent News
-
Mesothelioma Patients May Benefit From Use of Painkiller That Shows Ability to Fight Cancer
Last week MesotheliomaCounsel reported on the potential cancer-fighting benefits of aspirin. Now, researchers report that another painkiller, used to treat migraines and arthritis, has “significant anti-cancer properties.” The drug, that can also boost the immune system, may offer mesothelioma patients another option for treatment. In a Jan. 11 press release from the AntiCancer Fund, an …
Label: Featured Story
Posted on Thursday, Jan 28, 2016 -
Aspirin Clinical Trial Could Lead to Early Treatment Guidelines for Mesothelioma
For years, researchers and medical professionals have touted the benefits of aspirin. Often the go-to drug for minor aches and pains, aspirin is also prescribed as a daily antidote to help lower the risk of heart attack. Others claim a daily aspirin may reduce the incidence of cancers. Now, researchers in the UK are putting …
Label: Featured Story
Posted on Thursday, Jan 21, 2016 -
Mesothelioma Patients Stand to Benefit from FDA Approval of Keytruda as First Line Treatment for Melanoma
The unprecedented results for mesothelioma and melanoma patients being treated with Keytruda (pembrolizumab) have kept the drug in the spotlight over the last year. The benefits of the drug are continuing to impress as the U.S. Food and Drug Administration announced last month that Keytruda is now approved for first-line treatment in melanoma patients. FDA …
Label: Featured Story
Posted on Monday, Jan 18, 2016 -
FDA Grants Breakthrough Therapy Designation to Drug Targeting Biomarker Found in Lung Cancer and Mesothelioma Patients
Boehringer Ingelheim announced last month that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to its investigational cancer drug BI 1482694 for the treatment of non-small cell lung cancer (NSCLC). According to Boehringer Ingelheim, the maker of 1482694, the drug is targeted to NSCLC patients whose tumors have epidermal growth factor (EGFR) …
Label: Featured Story
Posted on Tuesday, Jan 12, 2016 -
Protein Found to Be a Key to Tumor Suppression in Lung Cancer, Possibly Mesothelioma
The protein p53 is one of the body’s most critical defenses in preventing the production of tumors, and if rendered defective, it could lead to uncontrolled tumor growth and metastasis in mesothelioma and other cancers. As a result, p53 protein has been gaining relevance among researchers as the key to killing cancer cells. Now, researchers …
Label: Featured Story
Posted on Monday, Dec 7, 2015 -
Merck/Pfizer Collaboration in Lung Cancer Clinical Trial Could Lead to Treatment Option for Mesothelioma
MesotheliomaCounsel has reported several times on the success Merck has had with its immunotherapy treatment Keytruda (pembrolizumab) in mesothelioma and lung cancer care. In addition, we have brought readers information on the benefits of Pfizer’s Xalkori (crizotinib) when treating lung cancer. Now, the two pharmaceutical giants are pairing up to combine the two treatments in …
Label: Featured Story
Posted on Tuesday, Nov 24, 2015 -
Clinical Trial Results Show Immunotherapy is Effective Against Mesothelioma
Scientists and researchers continue to make strides in finding new approaches to treating the persistent and indefatigable mesothelioma. Chemotherapy, once considered the primary mode of treatment for the terminal cancer, is beginning to take a back seat to immunotherapy. A review of recent clinical trials shows success with immunotherapy where chemotherapy failed in small cell …
Label: Featured Story
Posted on Monday, Nov 23, 2015 -
Opdivo Boosts Survival in Lung Cancer Patients, Could Benefit Mesothelioma Patients
In August, MesotheliomaCounsel reported on the “spectacular” results melanoma patients achieved when treated with nivolumab (Opdivo), an immunotherapy drug. Now, a new study reports lung cancer patients realized a nearly three month survival benefit with the drug over another treatment. These promising results give mesothelioma patients in the U.S. hope they will see similar results. …
Label: Featured Story
Posted on Tuesday, Nov 3, 2015 -
Sloan-Kettering “Pioneering” Use of MRI To Quickly, Accurately Determine Effectiveness of Cancer Treatment
Memorial Sloan-Kettering Cancer Center is dedicated to excellence in the prevention, treatment, and cure of cancer – and the center is continually innovating to achieve that goal. Last month, MesotheliomaHelp reported on the Center’s new approach to clinical trials using “Basket Studies.” Now, MSKCC is leading the way by appraising an innovative tool that can …
Label: Featured Story
Posted on Monday, Oct 12, 2015 -
Phase II Clinical Trial Stabilizes Peritoneal Mesothelioma Patients
Mesothelioma, a rare cancer with just 3,000 cases diagnosed in the U.S. each year, is under-represented in the medical community. Peritoneal mesothelioma, a cancer of the abdomen, is even rarer, representing just ten percent of all mesothelioma patients. Now, the disease is receiving some much-needed attention with several recent studies pointing to successful treatments. In …
Label: Featured Story
Posted on Thursday, Oct 8, 2015
